John Lebbos, M.D. vice president at Decision Resources is available to discuss methicillin-resistant Staphylococcus aureus (MRSA) with members of the media in the aftermath of the recently publicized outbreak of MRSA that has infected 18 mothers and 19 newborns over the past six months at Beth Israel Deaconess Medical Center in Boston, MA.

  Dr. Lebbos is available to discuss:    --  Therapies currently in use for the treatment of hospital-acquired       infections such as MRSA as well as drugs in the pipeline   --  The overall size of the MRSA drug market now and in the years ahead   --  The treatment attributes that surveyed physicians and thought leaders       indicate are the most important in their prescribing decisions for       MRSA   --  The unmet needs in the treatment of hospital-acquired infections such       as MRSA  

To speak with Dr. Lebbos, please contact Christopher Comfort at 781-296-2597 or 781-568-9135 or ccomfort@dresources.com.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Christopher Comfort   781-296-2597   ccomfort@dresources.com    /PRNewswire -- April 10/ 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

Small-Cell Lung Cancer Drug Market Will More Than Double to Over $684 Million in 2017

View Now